Rexahn Pharmaceuticals, Inc. (AMEX:RNN) announced initial data from its ongoing phase I dose-escalation study on Supinoxin (RX-5902). The drug was well tolerated in cancer patients with solid tumors.
The study is evaluating the safety, tolerability and dose limiting toxicities of Supinoxin as well as maximal tolerated dose (NYSE: MTD) in patients suffering from solid cancer tumors who have failed prior treatment with other approved therapies and whose disease has progressed.
Rexahn has completed three dosing cycles (25mg, 50mg and 100 mg) in the ongoing study. So far, no adverse incidents related to the dosing of Supinoxin have occurred and the fourth dosing cycle with 150 mg of Supinoxin has been initiated. The MTD is yet to be achieved. Initial data from the study showed that the pharmacokinetic profile and oral bioavailability of Supinoxin was similar to that observed in preclinical studies.
Meanwhile, Rexahn is advancing with its other oncology candidates, Archexin and RX-3117. Archexin is in a phase IIa proof-of-concept study in patients suffering from metastatic renal cell carcinoma (RCC). Additionally, RX-3117 is in a phase Ib study in patients with solid tumors. The company expects to complete enrolling patients for this study by the end of 2014. Data readout is expected in the first half of 2015.
We expect investor focus to remain on pipeline updates from the company.
Rexahn carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector include Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Amgen Inc. (NASDAQ: AMGN) and Gilead Sciences Inc. (NASDAQ: GILD). All these stocks carry a Zacks Rank #1 (Strong Buy).
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
ALEXION PHARMA (NASDAQ: ALXN): Free Stock Analysis Report
AMGEN INC (NASDAQ: AMGN): Free Stock Analysis Report
REXAHN PHARMACT (AMEX:RNN): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research